• 太原爱尔
  • 门诊:8:00-17:30
  • 0351-4720120
爱尔眼科·集团

爱尔眼科·集团

爱尔集团的介绍

爱尔眼科医院集团是具有中国及全球范围医院规模和优质医疗能力的眼科医疗集团,服务覆盖亚洲、欧洲和北美洲,在中国内地、欧洲、东南亚拥有3家上市公司(中国A股:爱尔眼科,300015;西班牙:CBAV;新加坡:40T)。目前在全球范围内开设眼科医院及中心达720家,其中中国内地611家、中国香港7家、美国1家、欧洲89家、东南亚12家。2020年,中国内地年门诊量超1000万人次,手术量超100万台,医疗服务网络覆盖全球近30亿人口。

AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide.

爱尔眼科始终坚持以国内发展为主线,国内国际双线并举,共同进步。在发展的过程中,致力于引进和吸收国际同步的眼科技术与医疗管理理念,以专业化、规模化、科学化为发展战略,推动中国眼科医疗事业的发展。通过不断实践,在充分吸收国际优质的医疗管理经验的基础上,成功探索出一套适应中国国情和市场环境的眼科医院连锁经营管理模式——“分级连锁”,充分发挥人才、技术和管理等方面的优势,提升诊疗质量、完善医疗服务、优化医患沟通。

Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way.

AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel.

科研创新、人才培养是长远发展的基石,爱尔眼科不断加大科研投入,大力支持开展前沿性、原创性的眼科学术研究,全力推进全球化平台上的眼健康生态圈战略。自2013年爱尔眼科与中南大学联合成立中南大学爱尔眼科学院,正式开启校企合作的创新探索以来,陆续推动了与湖北科技学院、武汉大学、暨南大学、安徽医科大学、天津大学、四川大学等知名高校的战略合作,充分发挥企业和高校的独特优势,在医院共建、人才培养、师资队伍建设、教学科研等领域展开深入合作,联手共建眼科医教研平台,合力打造“名校+名企”典范,为社会培养更多优秀的眼科医学人才,真正地为中国眼科学和视觉科学的创新发展贡献智慧与力量。

Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.

Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.

AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.

在此基础上,爱尔眼科持续打造立体化科研平台,截止目前已在全国范围内构建起“八所、二站、二基地、三中心”的创新型科教研一体化平台。“八所”:爱尔眼科研究所、爱尔眼视光研究所、爱尔角膜病研究所、爱尔屈光研究所、爱尔视网膜研究所、爱尔青光眼研究所、爱尔白内障与人工晶状体研究所、武汉爱尔眼科研究所。获批设立“二站”:国家博士后科研工作站、湖南省院士专家工作站;“二基地”:湖南省眼视光国际科技合作基地、湖南省“海智计划”工作基地;“三中心”:湖南省眼视光工程技术研究中心、湖南省眼表疾病临床医学研究中心、湖南省企业技术中心;联合共建“爱尔眼科-中科院计算所数字眼科联合实验室”等创新平台。

Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.

“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established.

上市十年之际,爱尔眼科以“创新驱动,科技爱尔”作为指导方针,提出三大战略目标。第一个目标是要将爱尔眼科的医疗服务网络覆盖到广大城乡县域,让老百姓在家门口就能享受到高质量的、可及的眼科医疗服务,助推健康中国战略。第二个目标是希望通过打造世界级及国家级的眼科医学中心,切实提高中国眼科医疗技术水平,赶超世界先进水平。第三个目标是希望通过全球化布局,医、教、研、产、投全面协同发展,推动人类眼科学与视觉科学进步。

On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment.

在十九年的创业发展历程中,爱尔眼科凝聚和培养了一批经验丰富、具有开拓创新精神的管理团队和医术精良、治学严谨的眼科专家和医生团队。截至目前,爱尔眼科医院集团及旗下全球员工总数达50000余人,其中眼科医生及视光师总数(含海外) 9000余人,包括一大批博士生导师、硕士生导师、博士、博士后、留学欧美的学者以及临床经验丰富的核心专家。

Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences.

爱尔眼科的发展壮大始终以“使所有人,无论贫穷富裕,都享有眼健康的权利”为初心和使命,致力于全人类的光明事业,坚持“以患者为中心”,追求社会责任和自身发展的和谐统一。通过开创性的“交叉补贴”模式,在为患者提供更高品质的眼科医疗服务的同时,全面开展防盲治盲工作、投身社会公益、帮助弱势群体,积极联合社会各界力量,推动中国防盲事业乃至国民眼健康事业的全面发展。2018年、2020年蝉联第十届、第十一届中国政府荣誉慈善奖项“中华慈善奖”、荣获中国公益年会“中国公益企业奖”、“最佳社会责任上市公司”、“湖南慈善奖”等荣誉。同时积极响应国家号召,作为中国代表企业牵头参与“一带一路光明行”、“湄公河光明行”等公益活动,获得组织者、受援国政府和患者的高度好评,逐步发展成为全球慈善公益活动的一张名片。

The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities.

爱尔眼科连续多年被专业机构评为“中国最受投资者尊重的上市公司前十强”,蝉联中国品牌节“华谱奖”,荣获“最佳持续投资价值奖”、“中国上市公司最佳股东回报奖”、“中国上市公司实业贡献大奖”等多项殊荣,成功入选沪深300指数股、MSCI中国大盘指数成份股等。

AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.

爱尔眼科医院集团是具有中国及全球范围医院规模和优质医疗能力的眼科医疗集团,服务覆盖亚洲、欧洲和北美洲,在中国内地、欧洲、东南亚拥有3家上市公司(中国A股:爱尔眼科,300015;西班牙:CBAV;新加坡:40T)。目前在全球范围内开设眼科医院及中心达720家,其中中国内地611家、中国香港7家、美国1家、欧洲89家、东南亚12家。2020年,中国内地年门诊量超1000万人次,手术量超100万台,医疗服务网络覆盖全球近30亿人口。

AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide.

爱尔眼科始终坚持以国内发展为主线,国内国际双线并举,共同进步。在发展的过程中,致力于引进和吸收国际同步的眼科技术与医疗管理理念,以专业化、规模化、科学化为发展战略,推动中国眼科医疗事业的发展。通过不断实践,在充分吸收国际优质的医疗管理经验的基础上,成功探索出一套适应中国国情和市场环境的眼科医院连锁经营管理模式——“分级连锁”,充分发挥人才、技术和管理等方面的优势,提升诊疗质量、完善医疗服务、优化医患沟通。

Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way.

AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel.

科研创新、人才培养是长远发展的基石,爱尔眼科不断加大科研投入,大力支持开展前沿性、原创性的眼科学术研究,全力推进全球化平台上的眼健康生态圈战略。自2013年爱尔眼科与中南大学联合成立中南大学爱尔眼科学院,正式开启校企合作的创新探索以来,陆续推动了与湖北科技学院、武汉大学、暨南大学、安徽医科大学、天津大学、四川大学等知名高校的战略合作,充分发挥企业和高校的独特优势,在医院共建、人才培养、师资队伍建设、教学科研等领域展开深入合作,联手共建眼科医教研平台,合力打造“名校+名企”典范,为社会培养更多优秀的眼科医学人才,真正地为中国眼科学和视觉科学的创新发展贡献智慧与力量。

Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.

Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.

AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.

在此基础上,爱尔眼科持续打造立体化科研平台,截止目前已在全国范围内构建起“八所、二站、二基地、三中心”的创新型科教研一体化平台。“八所”:爱尔眼科研究所、爱尔眼视光研究所、爱尔角膜病研究所、爱尔屈光研究所、爱尔视网膜研究所、爱尔青光眼研究所、爱尔白内障与人工晶状体研究所、武汉爱尔眼科研究所。获批设立“二站”:国家博士后科研工作站、湖南省院士专家工作站;“二基地”:湖南省眼视光国际科技合作基地、湖南省“海智计划”工作基地;“三中心”:湖南省眼视光工程技术研究中心、湖南省眼表疾病临床医学研究中心、湖南省企业技术中心;联合共建“爱尔眼科-中科院计算所数字眼科联合实验室”等创新平台。

Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.

“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established.

上市十年之际,爱尔眼科以“创新驱动,科技爱尔”作为指导方针,提出三大战略目标。第一个目标是要将爱尔眼科的医疗服务网络覆盖到广大城乡县域,让老百姓在家门口就能享受到高质量的、可及的眼科医疗服务,助推健康中国战略。第二个目标是希望通过打造世界级及国家级的眼科医学中心,切实提高中国眼科医疗技术水平,赶超世界先进水平。第三个目标是希望通过全球化布局,医、教、研、产、投全面协同发展,推动人类眼科学与视觉科学进步。

On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment.

在十九年的创业发展历程中,爱尔眼科凝聚和培养了一批经验丰富、具有开拓创新精神的管理团队和医术精良、治学严谨的眼科专家和医生团队。截至目前,爱尔眼科医院集团及旗下全球员工总数达50000余人,其中眼科医生及视光师总数(含海外) 9000余人,包括一大批博士生导师、硕士生导师、博士、博士后、留学欧美的学者以及临床经验丰富的核心专家。

Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences.

爱尔眼科的发展壮大始终以“使所有人,无论贫穷富裕,都享有眼健康的权利”为初心和使命,致力于全人类的光明事业,坚持“以患者为中心”,追求社会责任和自身发展的和谐统一。通过开创性的“交叉补贴”模式,在为患者提供更高品质的眼科医疗服务的同时,全面开展防盲治盲工作、投身社会公益、帮助弱势群体,积极联合社会各界力量,推动中国防盲事业乃至国民眼健康事业的全面发展。2018年、2020年蝉联第十届、第十一届中国政府荣誉慈善奖项“中华慈善奖”、荣获中国公益年会“中国公益企业奖”、“最佳社会责任上市公司”、“湖南慈善奖”等荣誉。同时积极响应国家号召,作为中国代表企业牵头参与“一带一路光明行”、“湄公河光明行”等公益活动,获得组织者、受援国政府和患者的高度好评,逐步发展成为全球慈善公益活动的一张名片。

The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities.

爱尔眼科连续多年被权威机构评为“中国最受投资者尊重的上市公司前十强”,蝉联中国品牌节“华谱奖”,荣获“最佳持续投资价值奖”、“中国上市公司最佳股东回报奖”、“中国上市公司实业贡献大奖”等多项殊荣,成功入选沪深300指数股、MSCI中国大盘指数成份股等。

AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.

爱尔集团的介绍

2002

爱尔眼科品牌创立 长沙、成都成立爱尔眼科医院

2003

爱尔眼科医院集团成立

2006

成立爱尔眼库:截至2021年已有10余家专业眼库,携手各地红十字成立27家角膜捐献登记接收站

2008

获中国医疗健康产业“年度最具成长企业”

2009

爱尔眼科股份有限公司成功上市

2010

获中国健康年度总评榜“全国最受欢迎眼科医院”

2013

被国家卫计委评为“消除白内障盲突出贡献单位” 中南大学爱尔眼科学院成立;爱尔眼科研究所成立

2014

获“2014中国年度雇主”奖 爱尔眼视光学院成立

2015

入选“2015年中国最有价值品牌500强” 成功申报国家自然科学基金委员会三项“国家自然科学基金”

2016

开启国际化战略,眼科医疗布局进入中国香港(亚洲医疗、理大护眼) 成立国家“湄公河五国光明行”对外医疗援助项目首批非公医疗执行机构; 获“最具社会责任上市公司”奖 获中华医学会授予“中华医学会优秀白内障手术技能培训基地” 携手国际眼科理事会(ICO),培养国际高端眼科人才

2017

加速国际化战略布局,进入美国、欧洲(美国Wang Vision眼科中心、欧洲巴伐利亚眼科) 开展“一带一路 光明行动”,作为中国民间慈善组织首次走出国门而备受关注; 参与“Clinica Baviera-stop Ceguera”公益慈善活动,帮助消除发展中国家可预防和可治疗的失明; 获“2017年度公益项目奖” 获国家自然科学基金委员会项目和青年科学基金项目资助

2018

获国家民政部颁发第十届“中华慈善奖” 获“2018中国品牌价值500强” 参与“澜湄光明行”,善举和高超的技艺得到国际广泛赞誉 加入世界眼科医院协会 发起全国首个由中国主导,全球近视大数据多中心研究项目 获“2017年中华医学科技进步一等奖”

2019年

上市十周年眼科医疗布局进入东南亚(东南亚ISEC眼科集团) “你是我的眼”—角膜移植公益行项目及万人复明工程项目,获中国慈善榜慈善项目奖、获中国慈善榜“十大慈善项目”奖 获得2023年第19届世界近视大会主办权(IMC2023)与武汉大学、暨南大学结成战略合作伙伴

2020年

助力国内外新冠疫情防控 为疫情防控捐赠财、物超5300余万元,各类应急支援队伍323个,2000余名医护人员加入防控疫情战线,230位医护人员进入武汉方舱医院等防疫一线; 驰援欧洲、东南亚海外地区医院,提供防疫物资; 获国务院扶贫办评选为“企业精准扶贫专项案例50佳”; 获中国红十字基金会年度“天使·杰出人道奉献奖”; 获向光奖“2020向善企业”称号 与安徽医科大学结成战略合作伙伴

2021年

获国家民政部颁发第十一届“中华慈善奖” 与中国科学院计算技术研究所联合启动“智能眼健康设备及大数据平台”; 与天津职业大学共建爱尔视光产业学院; 与天津大学、四川大学、深圳职业技术学院结成战略合作伙伴; “博士后科研工作站”正式揭牌; 建设爱尔国际医学院(本科院校)及附属三甲专科医院
#
#
咨询电话:0351-4720120